BDCRB (Synonyms: 2-Bromo-5,6-dichloro-1-β-D-ribofuranosyl benzimidazole)

目录号: HY-19296: FAQs
Data Sheet 产品使用指南技术支持

BDCRB 是一种选择性人巨细胞病毒 (HCMV) 抑制剂，通过阻断高分子量 DNA 的成熟裂解而发挥作用。BDCRB 对感染后 72 h 病毒产量的 IC₅₀ 为 0.03 μM 。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

BDCRB Chemical Structure

CAS No. : 142356-43-2

1. 客户无需承担相应的运输费用。

2. 同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

可免费申领三个不同产品的试用装。

3. 试用装只面向终端客户。

规格		是否有货
50 mg		询价
100 mg		询价
250 mg		询价

or 大包装询价

* Please select Quantity before adding items.

BDCRB 相关产品

•同靶点产品:

•同靶点蛋白产品:

生物活性
纯度 & 产品资料
参考文献

生物活性

BDCRB is a selective Human cytomegalovirus (HCMV) inhibitor through blocking the maturational cleavage of high-molecular-weight DNA. BDCRB shows a mean IC₅₀ of 0.03 μM for viral yield at 72 h postinfection^[1].

细胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
BSC-1	IC₅₀	130 μM Compound: BDCRB (table-1)	Inhibitory concentration required against herpes simplex virus type-1 (HSV-1) expressed in BSC-1 cells was determined by ELISA assay Inhibitory concentration required against herpes simplex virus type-1 (HSV-1) expressed in BSC-1 cells was determined by ELISA assay	[PMID: 15509176]
BSC-1	IC₅₀	130 μM Compound: BDCRB (table-1)	Inhibitory concentration required against herpes simplex virus type-1 (HSV-1) expressed in BSC-1 cells was determined by ELISA assay Inhibitory concentration required against herpes simplex virus type-1 (HSV-1) expressed in BSC-1 cells was determined by ELISA assay	[PMID: 15509175]
BSC-1	IC₅₀	130 μM Compound: BDCRB (table-1)	Inhibitory concentration required against herpes simplex virus type-1 (HSV-1) expressed in BSC-1 cells was determined by ELISA assay Inhibitory concentration required against herpes simplex virus type-1 (HSV-1) expressed in BSC-1 cells was determined by ELISA assay	[PMID: 15509174]
HFF	IC₅₀	0.3 μM Compound: 4b	Compound was tested for antiviral activity against wild-type Towne virus of HCMV in yield reduction assay using HFF cells Compound was tested for antiviral activity against wild-type Towne virus of HCMV in yield reduction assay using HFF cells	[PMID: 10882374]
HFF	IC₅₀	0.34 μM Compound: 4b	Compound was tested for antiviral activity against wild-type AD169 virus of HCMV in plaque reduction assay using HFF cells Compound was tested for antiviral activity against wild-type AD169 virus of HCMV in plaque reduction assay using HFF cells	[PMID: 10882374]
HFF	IC₅₀	0.41 μM Compound: 4b	Compound was tested for antiviral activity against 2916 strain of HCMV in plaque reduction assay using HFF cells Compound was tested for antiviral activity against 2916 strain of HCMV in plaque reduction assay using HFF cells	[PMID: 10882374]
HFF	IC₅₀	0.7 μM Compound: 4b	Compound was tested for antiviral activity against Towne strain of HCMV in a plaque reduction assay using HFF cells Compound was tested for antiviral activity against Towne strain of HCMV in a plaque reduction assay using HFF cells	[PMID: 10882374]
HFF	IC₅₀	0.7 μM Compound: BDCRB (table-1)	Inhibitory concentration required against human cytomegalovirus (HCMV) expressed in HFF cells was determined by plaque reduction assay Inhibitory concentration required against human cytomegalovirus (HCMV) expressed in HFF cells was determined by plaque reduction assay	[PMID: 15509176]
HFF	IC₅₀	0.7 μM Compound: BDCRB (table-1)	Inhibitory concentration required against human cytomegalovirus (HCMV) expressed in HFF cells was determined by plaque reduction assay Inhibitory concentration required against human cytomegalovirus (HCMV) expressed in HFF cells was determined by plaque reduction assay	[PMID: 15509175]
HFF	IC₅₀	0.7 μM Compound: BDCRB (table-1)	Inhibitory concentration required against human cytomegalovirus (HCMV) expressed in HFF cells was determined by plaque reduction assay Inhibitory concentration required against human cytomegalovirus (HCMV) expressed in HFF cells was determined by plaque reduction assay	[PMID: 15509174]
HFF	IC₅₀	0.7 μM Compound: 5	Compound was tested for antiviral activity against human cytomegalovirus (HCMV) by plaque reduction assay using HFF cells Compound was tested for antiviral activity against human cytomegalovirus (HCMV) by plaque reduction assay using HFF cells	[PMID: 10882375]
HFF	IC₅₀	0.99 μM Compound: BDCRB (table-1)	Inhibitory concentration required against human cytomegalovirus (HCMV) wild type expressed in HFF cells was determined by plaque reduction assay Inhibitory concentration required against human cytomegalovirus (HCMV) wild type expressed in HFF cells was determined by plaque reduction assay	[PMID: 15509176]
HFF	IC₅₀	1.7 μM Compound: 4b	Compound was tested for antiviral activity against wild-type Towne virus of HCMV in plaque reduction assay using HFF cells Compound was tested for antiviral activity against wild-type Towne virus of HCMV in plaque reduction assay using HFF cells	[PMID: 10882374]
HFF	IC₅₀	118 μM Compound: BDCRB (table-1)	Cytotoxicity produced in stationary HFF cells was determined by microscopic inspection of uninfected cells Cytotoxicity produced in stationary HFF cells was determined by microscopic inspection of uninfected cells	[PMID: 15509176]
HFF	IC₅₀	118 μM Compound: BDCRB (table-1)	Cytotoxicity produced in stationary HFF cells was determined by microscopic inspection of uninfected cells Cytotoxicity produced in stationary HFF cells was determined by microscopic inspection of uninfected cells	[PMID: 15509175]
HFF	IC₅₀	118 μM Compound: BDCRB (table-1)	Cytotoxicity produced in stationary HFF cells was determined by microscopic inspection of uninfected cells Cytotoxicity produced in stationary HFF cells was determined by microscopic inspection of uninfected cells	[PMID: 15509174]
HFF	IC₅₀	118 μM Compound: 1b (BDCRB)	Concentration required to inhibit stationary human HFF cell line growth was determined by microscopy examination Concentration required to inhibit stationary human HFF cell line growth was determined by microscopy examination	[PMID: 15509173]
HFF	IC₅₀	118 μM Compound: 4b	Compound was tested for visual cytotoxicity on HFF cells unaffected by HCMV at the time of plaque enumeration Compound was tested for visual cytotoxicity on HFF cells unaffected by HCMV at the time of plaque enumeration	[PMID: 10882374]
HFF	IC₅₀	12 μM Compound: BDCRB (table-1)	Inhibitory concentration required against human cytomegalovirus (HCMV) D10 strain (UL89 mutant gene) expressed in HFF cells was determined by plaque reduction assay Inhibitory concentration required against human cytomegalovirus (HCMV) D10 strain (UL89 mutant gene) expressed in HFF cells was determined by plaque reduction assay	[PMID: 15509176]
HFF	IC₅₀	29 μM Compound: BDCRB (table-1)	Inhibitory concentration required against human cytomegalovirus (HCMV) C4 strain (UL56 + UL89 mutant gene) expressed in HFF cells was determined by plaque reduction assay Inhibitory concentration required against human cytomegalovirus (HCMV) C4 strain (UL56 + UL89 mutant gene) expressed in HFF cells was determined by plaque reduction assay	[PMID: 15509176]
HFF	IC₅₀	31 μM Compound: 4b	Compound was tested for antiviral activity against C-4 Towne virus of HCMV in plaque reduction assay using HFF cells Compound was tested for antiviral activity against C-4 Towne virus of HCMV in plaque reduction assay using HFF cells	[PMID: 10882374]
HFF	CC₅₀	313.6 μM Compound: BDCRB	Cytotoxicity against HFF after 8 days by XTT assay Cytotoxicity against HFF after 8 days by XTT assay	[PMID: 19786605]
HFF	IC₅₀	6.7 μM Compound: BDCRB (table-1)	Inhibitory concentration required against human cytomegalovirus (HCMV) r56 strain (UL56 mutant gene) expressed in HFF cells was determined by plaque reduction assay Inhibitory concentration required against human cytomegalovirus (HCMV) r56 strain (UL56 mutant gene) expressed in HFF cells was determined by plaque reduction assay	[PMID: 15509176]
HFF	IC₅₀	8 μM Compound: 4b	Compound was tested for antiviral activity against C-4 Towne virus of HCMV in yield reduction assay using HFF cells Compound was tested for antiviral activity against C-4 Towne virus of HCMV in yield reduction assay using HFF cells	[PMID: 10882374]
KB	IC₅₀	> 100 μM Compound: BDCRB (table-1)	Cytotoxicity against KB cells was determined by crystal violet staining and spectrophotometric quantitation of dye eluted from stained cells Cytotoxicity against KB cells was determined by crystal violet staining and spectrophotometric quantitation of dye eluted from stained cells	[PMID: 15509176]
KB	IC₅₀	> 100 μM Compound: BDCRB (table-1)	Cytotoxicity against KB cells was determined by crystal violet staining and spectrophotometric quantitation of dye eluted from stained cells Cytotoxicity against KB cells was determined by crystal violet staining and spectrophotometric quantitation of dye eluted from stained cells	[PMID: 15509175]
KB	IC₅₀	> 100 μM Compound: BDCRB (table-1)	Cytotoxicity against KB cells was determined by crystal violet staining and spectrophotometric quantitation of dye eluted from stained cells Cytotoxicity against KB cells was determined by crystal violet staining and spectrophotometric quantitation of dye eluted from stained cells	[PMID: 15509174]
KB	IC₅₀	> 100 μM Compound: 1b (BDCRB)	Concentration required to inhibit KB cell line growth was determined by crystal violet staining method Concentration required to inhibit KB cell line growth was determined by crystal violet staining method	[PMID: 15509173]
NIH3T3	CC₅₀	88.1 μM Compound: BDCRB	Cytotoxicity against mouse NIH/3T3 cells after 8 days by XTT assay Cytotoxicity against mouse NIH/3T3 cells after 8 days by XTT assay	[PMID: 19786605]

分子量

398.04

Formula

C₁₂H₁₁BrCl₂N₂O₄

CAS 号

142356-43-2

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

纯度 & 产品资料

产品使用指南 (1538 KB)

参考文献

[1]. Biron KK, et al. Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action. Antimicrob Agents Chemother. 2002 Aug;46(8):2365-72. [Content Brief]

BDCRB 相关分类

Infection

摩尔计算器
稀释计算器

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量		浓度		体积		分子量 *
	=		×		×

The dilution calculator equation

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

浓度 _(start)	×	体积 _(start)	=	浓度 _(final)	×	体积 _(final)
	×		=		×
C1		V1		C2		V2

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

BDCRB142356-43-22-Bromo-5,6-dichloro-1-β-D-ribofuranosyl benzimidazoleOthersHCMVmaturational cleavageInhibitorinhibitorinhibit

您最近查看的产品:

产品名称：

* 需求量：

* 客户姓名：

* Email：

* 电话：

* 公司或机构名称：

留言给我们：

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2025 MedChemExpress. All Rights Reserved.

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。

站点地图隐私声明

沪ICP备15051369号-4

上海工商

沪公网安备31011502019417

沪(浦)应急管危经许[2021]201709(QFYS)

营业执照（三证合一）

BDCRB (Synonyms: 2-Bromo-5,6-dichloro-1-β-D-ribofuranosyl benzimidazole)

BDCRB 相关产品

•同靶点产品:

•同靶点蛋白产品:

生物活性

纯度 & 产品资料

参考文献

BDCRB 相关分类

摩尔计算器

稀释计算器

The molarity calculator equation

The dilution calculator equation

Keywords:

您最近查看的产品:

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

产品名称：			* Lot #：
* 客户姓名：			* Email：
电话：			* 部门：
* 公司或机构名称：
留言给我们：

姓名
邮箱 *

Sorry, but the email address you supplied was invalid.

BDCRB (Synonyms: 2-Bromo-5,6-dichloro-1-β-D-ribofuranosyl benzimidazole)

BDCRB 相关抗体

BDCRB 相关产品

•同靶点产品:

•同靶点蛋白产品:

生物活性

纯度 & 产品资料

参考文献

BDCRB 相关分类

摩尔计算器

稀释计算器

The molarity calculator equation

The dilution calculator equation

Keywords:

您最近查看的产品:

Request for HNMR Report

Request for HNMR Report

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z